[go: up one dir, main page]

PT968182E - Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt - Google Patents

Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt

Info

Publication number
PT968182E
PT968182E PT97935666T PT97935666T PT968182E PT 968182 E PT968182 E PT 968182E PT 97935666 T PT97935666 T PT 97935666T PT 97935666 T PT97935666 T PT 97935666T PT 968182 E PT968182 E PT 968182E
Authority
PT
Portugal
Prior art keywords
hydroxamic
carboxylic acid
acid derivatives
mpm
inhibiting activity
Prior art date
Application number
PT97935666T
Other languages
English (en)
Inventor
John Gary Montana
Andrew Douglas Baxter
David Alan Owen
Robert John Watson
John Fraser Keily
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of PT968182E publication Critical patent/PT968182E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
PT97935666T 1996-08-07 1997-08-07 Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt PT968182E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
PT968182E true PT968182E (pt) 2004-08-31

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97935666T PT968182E (pt) 1996-08-07 1997-08-07 Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt

Country Status (17)

Country Link
US (1) US6118001A (pt)
EP (1) EP0968182B1 (pt)
JP (1) JP2000517297A (pt)
KR (1) KR20000029858A (pt)
CN (1) CN1227540A (pt)
AT (1) ATE266000T1 (pt)
AU (1) AU730464B2 (pt)
BR (1) BR9711027A (pt)
CA (1) CA2263154A1 (pt)
CZ (1) CZ297278B6 (pt)
DE (1) DE69729007T2 (pt)
DK (1) DK0968182T3 (pt)
ES (1) ES2217425T3 (pt)
NO (1) NO314452B1 (pt)
PL (1) PL193829B1 (pt)
PT (1) PT968182E (pt)
WO (1) WO1998005635A1 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032734A1 (en) * 1997-01-22 1998-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. SUBSTITUTED β-THIOCARBOXYLIC ACIDS
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
CA2283275A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
HUP0100812A3 (en) 1997-11-21 2002-11-28 Upjohn Co Alpha-hydroxy, -amino and -fluoro derivatives of betha-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
EP0965592A1 (en) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Process for preparing 3-arylsulfur hydroxamic acids
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU5634999A (en) * 1998-08-29 2000-03-21 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
GB9911073D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9911075D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
JP2003524008A (ja) * 2000-02-21 2003-08-12 アストラゼネカ・アクチエボラーグ アリールピペラジンおよびアリールピペリジン、およびそれらのメタロプロテイナーゼ阻害剤としての使用
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2001087844A1 (en) * 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003099272A1 (en) 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2486402C (en) * 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
DE10226370B4 (de) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrat für ein elektronisches Bauteil, Verwendung des Substrates, Verfahren zur Erhöhung der Ladungsträgermobilität und Organischer Feld-Effekt Transistor (OFET)
DE10233085B4 (de) 2002-07-19 2014-02-20 Dendron Gmbh Stent mit Führungsdraht
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
AU2006239546B2 (en) * 2005-04-25 2010-04-15 Novartis Ag Imidazo(1,2-A)pyridine derivatives useful as peptide deformylase (PDF) inhibitors
EP3002330A1 (en) 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0604142D0 (en) 2006-03-01 2006-04-12 Sterix Ltd Compound
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
CA2672267C (en) 2006-07-27 2016-05-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
AU2009217354B2 (en) 2008-02-22 2013-10-10 Covidien Lp Methods and apparatus for flow restoration
PL3192874T3 (pl) 2008-06-18 2020-06-29 Oxford Biomedica (Uk) Limited Oczyszczanie wirusa
WO2010055413A1 (en) 2008-11-12 2010-05-20 Fondazione Centro San Raffaele Del Monte Tabor Gene vector for inducing transgene-specific immune tolerance
PT2424571T (pt) 2009-04-30 2020-05-06 Ospedale San Raffaele Srl Vetor génico
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
WO2014121884A1 (en) 2013-02-06 2014-08-14 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
EP2968568A2 (en) 2013-03-11 2016-01-20 Life Science Nutrition AS Natural lipids containing non-oxidizable fatty acids
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
EP3060670B1 (en) 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Method
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
GB201418965D0 (pt) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201608944D0 (en) 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
DE102017211110A1 (de) * 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh Verfahren zur Herstellung eines Silans, Verfahren zur Modifizierung einer Kieselsäure mit dem Silan und modifizierte Kieselsäure
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
GB201807944D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
WO2020002380A1 (en) 2018-06-25 2020-01-02 Ospedale San Raffaele S.R.L Gene therapy
US20220056484A1 (en) 2018-10-11 2022-02-24 Ospedale San Raffaele S.R.L. Selection by means of artificial transactivators
JP2022517342A (ja) 2019-01-18 2022-03-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法
EP4058067A1 (en) 2019-11-12 2022-09-21 Oxford BioMedica (UK) Limited Production system
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクターの製造
JP2023516493A (ja) 2020-03-13 2023-04-19 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクター
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
CA3188667A1 (en) 2020-09-28 2022-03-31 Nicola Vannini Compositions and methods for increasing stem cell function
US20240010981A1 (en) 2020-09-28 2024-01-11 Societe Des Produits Nestle S.A. Compositions and methods for increasing stem cell function
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
JP2024506751A (ja) 2021-02-01 2024-02-14 イプシレン バイオ エス．アール．エル． 遺伝子サイレンシング
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
JP2024516187A (ja) 2021-05-05 2024-04-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるためのウロリチン
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods
WO2024252342A1 (en) 2023-06-08 2024-12-12 Fondazione Telethon Ets Genetic modification protocols in immune cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098824A (en) * 1975-10-02 1978-07-04 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
CH630606A5 (en) * 1977-02-15 1982-06-30 Lafon Labor Phenylamidine derivatives useful especially in therapeutics
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
JPH11504645A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド ペプチジル化合物およびその治療的使用
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
JP4358908B2 (ja) * 1996-01-02 2009-11-04 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換（アリール、ヘテロアリール、アリールメチル又はヘテロアリールメチル）ヒドロキサム酸化合物
JP2001516338A (ja) * 1996-09-27 2001-09-25 ファルマシア・アンド・アップジョン・カンパニー マトリックスメタロプロテイナーゼ・インヒビターとしてのβ―スルホニルヒドロキサム酸
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Also Published As

Publication number Publication date
NO990543D0 (no) 1999-02-05
CZ36899A3 (cs) 1999-07-14
CN1227540A (zh) 1999-09-01
EP0968182B1 (en) 2004-05-06
ATE266000T1 (de) 2004-05-15
BR9711027A (pt) 1999-08-17
WO1998005635A1 (en) 1998-02-12
AU3856497A (en) 1998-02-25
CZ297278B6 (cs) 2006-10-11
KR20000029858A (ko) 2000-05-25
NO314452B1 (no) 2003-03-24
JP2000517297A (ja) 2000-12-26
PL331598A1 (en) 1999-08-02
NO990543L (no) 1999-04-06
DK0968182T3 (da) 2004-08-16
CA2263154A1 (en) 1998-02-12
DE69729007T2 (de) 2005-04-07
ES2217425T3 (es) 2004-11-01
PL193829B1 (pl) 2007-03-30
EP0968182A1 (en) 2000-01-05
DE69729007D1 (de) 2004-06-09
US6118001A (en) 2000-09-12
AU730464B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
PT968182E (pt) Derivados de acidos hidroxamicos e carboxilicos com actividade inibidora da mpm e do fnt
MY119711A (en) Method of inhibiting photoaging of skin
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
ATE413386T1 (de) Ppar-gamma modulatoren
TR199900781T2 (xx) H�cre yap��ma inhibit�rleri
ATE222889T1 (de) Hydroxamsäure-derivate
PT934259E (pt) Acidos beta-sulfonamido hidroxamicos como inibidores de metaloproteinases de matriz e de tace
PT946166E (pt) Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
IL123431A0 (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF)
BG109411A (en) METHOD FOR OBTAINING HIV-PROTEZATE INHIBITORS
EP0994707A4 (en) INHIBITORS OF NAALADASE ENZYME ACTIVITY
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
NO20003828L (no) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinase inhibitorer
PT1214302E (pt) 3-fenil-5-alcoxi-1,3,4-oxadiazol-2-onas substituidas e sua utilizacao como inibidores de lipase
DE69928244D1 (de) Inhibitoren der nf-kb aktivierung
ATE193560T1 (de) Analytisches und therapeutisches mittel
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
UA30338A (uk) Спосіб оцінки ефективності лікування нейрогенних розладів сечовипускання
PT828483E (pt) Utilizacao de derivados de tropolona como inibidores da enzima inositol monofosfatase
BR9803717A (pt) ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase.